Volpara Health Technologies will now operate under the Lunit brand, building on the latter's 2024 acquisition of Volpara.
This move aims to merge the two firms' respective technologies in breast health and AI. Lunit International (formerly Volpara Health Technologies), which includes all former Volpara operations across the U.S., Oceania, Europe, and Asia, will lead Lunit’s business development and customer engagement efforts in these markets.
Lunit is also transitioning part of its global sales organization into these regional hubs. The company said this will allow the Seoul headquarters to focus on AI research, innovation, and new product development.
Part of the move also includes a newly designed website launched by Lunit.
